Cardiovascular Prognosis of Subclinical Chronic Obstructive Pulmonary Disease in Patients with Suspected or Confirmed Coronary Artery Disease

References

• Vogelmeier C. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2020 report [Internet]. Fontana: Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2020:141. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed August 14, 2023.
   Google Scholar
• The top 10 causes of death [Internet]. Newsroom: fact sheets. Geneva: World Health Organization; 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed August 14, 2023.
   Google Scholar
• Macedo L, Lacerda EM, Markman-Filho B, et al. Tendências da morbidade e mortalidade da DPOC no Brasil, de 2000 a 2016 [Trends in COPD morbidity and mortality in Brazil, from 2000 to 2016]. J Bras Pneumol. 2019;45(6):e20180402. Portuguese. doi:10.1590/1806-3713/e20180402
   PubMedGoogle Scholar
• King P. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. King Clin Trans Med. 2015;4:26.
   PubMedGoogle Scholar
• Enriquez J, Parikh SV, Selzer F, et al. Increased adverse events after percutaneous coronary intervention in patients with COPD. Chest. 2011;140(3):604–610. doi:10.1378/chest.10-2644
   PubMed Web of Science ®Google Scholar
• Zhang M, Cheng Y-J, Zheng W, et al. Impact of chronic obstructive pulmonary disease on long-term outcome in patients with coronary artery disease undergoing percutaneous coronary intervention. Biomed Res Int. 2016;2016:8212459. doi:10.1155/2016/8212459
   PubMed Web of Science ®Google Scholar
• Mannino DM, Higuchi K, T-c Y, et al. Economic burden of chronic obstructive pulmonary disease by presence of comorbidities. Chest. 2014;147:1199–1201. doi:10.1378/chest.15-0380
   Web of Science ®Google Scholar
• Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardio- vascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639. doi:10.1016/S2213-2600(15)00241-6
   PubMed Web of Science ®Google Scholar
• Daher A, Dreher M. The bidirectional relationship between chronic obstructive pulmonary disease and coronary artery disease. Herz. 2020;45:110–117. doi:10.1007/s00059-020-04893-4
   PubMed Web of Science ®Google Scholar
• Boschetto P, Beghé B, Fabbri LM, Ceconi C. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology. 2012;17(3):422–431. doi:10.1111/j.1440-1843.2011.02118.x
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27. doi:10.1016/j.jaci.2016.05.011
   PubMed Web of Science ®Google Scholar
• Hasan A, Ansari N, Parvez A, Beg M, Bhargava R. Understanding the relation between COPD and coronary artery disease. J Indian Acad Clin Med. 2014;15(2):120–124.
   Google Scholar
• Papaioannou AI, Bartziokas K, Loukides S, et al. Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk? Eur Respir J. 2015;46(3):846–849. doi:10.1183/09031936.00237014
   PubMed Web of Science ®Google Scholar
• Roversi S, Roversi P, Spadafora G, Rossi R, Fabbri LM. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest. 2014;44(1):93–102. doi:10.1111/eci.12181
   PubMed Web of Science ®Google Scholar
• Kart L, Akkoyunlu ME, Bayram M, et al. COPD: an underdiagnosed disease at hospital environment. Wien Klin Wochenschr. 2014;126(3–4):73–78. doi:10.1007/s00508-013-0458-4
   PubMed Web of Science ®Google Scholar
• Pizarro C, Linnhoff F, van Essen F, et al. Lower extremity and carotid artery disease in COPD. ERJ Open Res. 2016;2(4):00037–02016. doi:10.1183/23120541.00037-2016
   PubMedGoogle Scholar
• Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014;69(8):718–723. doi:10.1136/thoraxjnl-2012-203151
   PubMed Web of Science ®Google Scholar
• Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. doi:10.1136/thx.54.7.581
   PubMed Web of Science ®Google Scholar
• Kovelis D, Segretti NO, Probst VS, Lareau SC, Brunetto AF, Pitta F. Validação do Modified Pulmonary Functional Status and dyspnea questionnaire e da escala do Medical Research Council para o uso em pacientes com doença pulmonar obstrutiva crônica no Brasil [Validation of the Modified Pulmonary Functional Status and dyspnea questionnaire and the Medical Research Council scale for use in patients with chronic obstructive pulmonary disease in Brazil]. J Bras Pneumol. 2008;34(12):1008–1018. Portuguese. doi:10.1590/S1806-37132008001200005
   PubMedGoogle Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirom- etry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805
   PubMed Web of Science ®Google Scholar
• Pereira CADC. Espirometria. J Bras Pneumol. 2002;28(Suppl 3):S1–S82.
   Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP
   PubMed Web of Science ®Google Scholar
• Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2021 Nov 30;144(22):e455]. Circulation. 2021;144(22):e368–e454. doi:10.1161/CIR.0000000000001029
   Web of Science ®Google Scholar
• Sara L, Szarf G, Tachibana A, et al. II Diretriz de Ressonância Magnética e Tomografia Computadorizada Cardiovascular da Sociedade Brasileira de Cardiologia e do Colégio Brasileiro de Radiologia [II Guidelines for Cardiovascular Magnetic Resonance and Computed Tomography of the Brazilian Society of Cardiology and the Brazilian College of Radiology]. Arq Bras Cardiol. 2014;103(6 Suppl 3):1–86. Portuguese. doi:10.5935/abc.2014S006
   PubMedGoogle Scholar
• Scanlon PJ, Faxon DP, Audet A, et al. ACC/AHA practice guidelines ACC/AHA guidelines for coronary angiography. J Am Coll Cardiol. 1999;33(6):1756–1824. doi:10.1016/s0735-1097(99)00126-6
   PubMed Web of Science ®Google Scholar
• Bosco E, Hsueh L, McConeghy KW, et al. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;21(1):241. doi:10.1186/s12874-021-01440-5
   PubMed Web of Science ®Google Scholar
• Poudel I, Tejpal C, Rashid H, Jahan N. Major adverse cardiovascular events: an inevitable outcome of ST elevation myocardial infarction? A literature review. Cureus. 2019;11(7):e5280. doi:10.7759/cureus.5280
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. L. Erlbaum Associates; 1988:147–149. doi:10.4324/9780203771587
   Google Scholar
• Mota IL, Sousa ACS, Almeida MLD, et al. Coronary lesions in patients with COPD (Global Initiative for Obstructive Lung Disease Stages I–III) and suspected or confirmed coronary arterial disease. Int J Chron Obstruct Pulmon Dis. 2018;13:1999–2006. doi:10.2147/COPD.S162713
   PubMed Web of Science ®Google Scholar
• Dursunoglu N, Dursunoglu D, Yıldız Aİ, Uludag B, Alaçam ZN, Sarıçopur A. Severity of coronary atherosclerosis in patients with COPD. Clin Respir J. 2017;11(6):751–756. PMID: 266055171. doi:10.1111/crj.12412
   PubMed Web of Science ®Google Scholar
• Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008. BMC Pulm Med. 2012;12(1):26. doi:10.1186/1471-2466-12-26
   PubMed Web of Science ®Google Scholar
• Soriano JB, Rigo F, Guerrero D, et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest. 2010;137(2):333–340. doi:10.1378/chest.09-1264
   PubMed Web of Science ®Google Scholar
• Mooe T, Stenfors N. The prevalence of COPD in individuals with acute coronary syndrome: a Spirometry-Based Screening Study, COPD. J Chron Obstruct Pulmon Dis. 2015;12(4):453–461. doi:10.3109/15412555.2014.974742
   PubMed Web of Science ®Google Scholar
• Mullerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in chronic obstructive pulmonary disease: systematic literature review. Chest. 2013;144:1163–1178. doi:10.1378/chest.12-2847
   PubMed Web of Science ®Google Scholar
• Eriksson B, Lindberg A, Mullerova H, Ronmark E, Lundback B. Association of heart diseases with COPD and restrictive lung function–results from a population survey. Respir Med. 2013;107:98–106. doi:10.1016/j.rmed.2012.09.011
   PubMed Web of Science ®Google Scholar
• de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez JM, Frances JF, Lozano PV, Bellón-Cano JM; CONSISTE study group. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis. 2012;7:679–686. PMID: 23055717; PMCID: PMC3468057. doi:10.2147/COPD.S36222
   PubMed Web of Science ®Google Scholar
• Hadi HA, Zubaid M, Mahmeed WA, et al. Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome. Clin Cardiol. 2010;33(4):228–235. PMID: 20394044; PMCID: PMC6653010. doi:10.1002/clc.20751
   PubMed Web of Science ®Google Scholar
• Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337–349. PMID: 19802349; PMCID: PMC2754086. doi:10.2147/copd.s6400
   PubMedGoogle Scholar
• Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128(4):2640–2646. doi:10.1378/chest.128.4.2640
   PubMed Web of Science ®Google Scholar
• Gupta AS, Rajesh V, James P. Cardiovascular comorbidities associated with patients with chronic obstructive pulmonary disease – a hospital-based study. Egypt J Bronchol. 2019;13(5):591–595. doi:10.4103/ejb.ejb_64_19
   Google Scholar
• Lin W-C, Chen C-W, Lu C-L. The association between recent hospitalized COPD exacerbations and adverse outcomes after percutaneous coronary intervention: a nationwide cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:169–179. doi:10.2147/COPD.S187345
   PubMed Web of Science ®Google Scholar
• Jatene T, Biering-Sørensen T, Nochioka K, et al. on behalf of the BASKET-PROVE investigators, frequency of cardiac death and stent thrombosis in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention (From the BASKET-PROVE I and II Trials). Am J Cardiol. 2016. doi:10.1016/j.amjcard.2016.09.013
   Google Scholar
• Campo G, Guastaroba P, Marzocchi A, et al. Impact of COPD on long-term outcome after St-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest. 2013;144(3):750–757. doi:10.1378/chest.12-2313
   PubMed Web of Science ®Google Scholar
• Pavasini R, Biscaglia S, d’Ascenzo F, et al. Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis. COPD. 2016;13(4):509–514. doi:10.3109/15412555.2015.1099620
   PubMedGoogle Scholar
• Harrison MT, Short P, Williamson PA, et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014;69(7):609–615. doi:10.1136/thoraxjnl-2013-203996
   PubMed Web of Science ®Google Scholar
• Ekstrom MP, Hermansson AB, Strom KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):715–720. doi:10.1164/rccm.201208-1565OC
   PubMed Web of Science ®Google Scholar
• Lahousse L, Loth DW, Joos GF, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther. 2013;26(2):212–217. doi:10.1016/j.pupt.2012.10.008
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Cazzola M. β-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives. Drugs. 2013;73(15):1653–1663. doi:10.1007/s40265-013-0120-5
   PubMed Web of Science ®Google Scholar
• Chang CL, Mills GD, McLachlan JD, et al. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J. 2010;40(3):193–200. doi:10.1111/j.1445-5994.2009.01943.x
   PubMed Web of Science ®Google Scholar
• Leung JM, Sin DD. Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. BMJ. 2017;358:j3772. doi:10.1136/bmj.j3772
   PubMed Web of Science ®Google Scholar
• Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;4:CD003566.
   Google Scholar
• Albouaini K, Andron M, Alahmar A, et al. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis. 2007;2(4):535–540.
   PubMedGoogle Scholar
• Van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008;178:695–700. doi:10.1164/rccm.200803-384OC
   PubMed Web of Science ®Google Scholar
• Lalmohamed A, Stojanovic D, Durand M, et al. Benefits of beta blockers in COPD patients and immortal/immeasurable time bias. BMJ. 2011;342:d2549. doi:10.1136/bmj.d2549
   PubMedGoogle Scholar
• Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27(149):180057. doi:10.1183/16000617.0057-2018
   PubMed Web of Science ®Google Scholar
• Li X-F, Mao Y-M. Beta-blockers in COPD: a systematic review based on recent research, Life Sci. 2020;252:117649. doi:10.1016/j.lfs.2020.117649
   PubMed Web of Science ®Google Scholar
• Higuchi S, Kohno T, Kohsaka S, et al. Different impact of beta-blockers on long-term mortality in heart failure patients with and without chronic obstructive pulmonary disease. J Clin Med. 2021;10:4378. doi:10.3390/jcm10194378
   PubMed Web of Science ®Google Scholar
• Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12:48. doi:10.1186/1471-2466-12-48
   PubMedGoogle Scholar
• Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med. 2019;381(24):2304–2314. doi:10.1056/NEJMoa1908142
   PubMed Web of Science ®Google Scholar